search button

Polymorphic variants in the vitamin D pathway genes and the risk of ovarian cancer among non-carriers of BRCA1/BRCA2 mutations

  • Authors:
    • Adrianna Mostowska
    • Stefan Sajdak
    • Piotr Pawlik
    • Margarita Lianeri
    • Paweł P. Jagodzinski

  • View Affiliations

  • Published online on: December 15, 2015     https://doi.org/10.3892/ol.2015.4033
  • Pages: 1181-1188
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous studies have produced inconsistent results regarding the contribution of single‑nucleotide polymorphisms (SNPs) in the vitamin D receptor (VDR) gene to ovarian cancer (OC) in various ethnicities. Additionally, little has been established with regard to the role of SNPs located in the retinoid X receptor α (RXRA), vitamin D‑binding protein [also know as group‑specific component (GC)] and VDR genes in non‑carriers of the breast cancer 1/2 early onset (BRCA1/BRCA2) gene mutations. All participating individuals in the present study were evaluated for BRCA1 mutations (5382incC, C61G and 4153delA) with HybProbe assays, and for BRCA2 mutation (5946delT) using high‑resolution melting (HRM) analysis. The associations of 8 SNPs located in RXRA, GC and VDR were investigated in OC patients without the BRCA1/BRCA2 mutations (n=245) and healthy controls (n=465). Genotyping of RXRA rs10881578 and rs10776909, and GC rs1155563 and rs2298849 SNPs was conducted by HRM analysis, while RXRA rs749759, GC rs7041, VDR BsmI rs1544410 and FokI rs2228570 genotyping was performed by polymerase chain reaction‑restriction fragment length polymorphism analysis. In addition, the gene‑gene interactions among all tested SNPs were studied using the epistasis option in PLINK software. The lowest P‑values of the trend test were identified for VDR rs1544410 and GC rs2298849 as Ptrend=0.012 and Ptrend=0.029, respectively. It was also found that, in the dominant inheritance model, VDR BsmI contributed to an increased risk of OC [odds ratio (OR), 1.570; 95% confidence interval (CI), 1.136‑2.171; P=0.006; Pcorr=0.048]. The gene‑gene interaction analysis indicated a significant interaction between RXRA rs749759 and VDR FokI rs2228570 (OR for interaction, 1.687; χ2=8.278; asymptotic P‑value=0.004; Pcorr=0.032). In conclusion, this study demonstrated that certain VDR and RXRA SNPs may be risk factors for OC in non-carriers of BRCA1/BRCA2 mutations in the Polish population.
View References

Related Articles

Journal Cover

February-2016
Volume 11 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Mostowska A, Sajdak S, Pawlik P, Lianeri M and Jagodzinski PP: Polymorphic variants in the vitamin D pathway genes and the risk of ovarian cancer among non-carriers of BRCA1/BRCA2 mutations. Oncol Lett 11: 1181-1188, 2016
APA
Mostowska, A., Sajdak, S., Pawlik, P., Lianeri, M., & Jagodzinski, P.P. (2016). Polymorphic variants in the vitamin D pathway genes and the risk of ovarian cancer among non-carriers of BRCA1/BRCA2 mutations. Oncology Letters, 11, 1181-1188. https://doi.org/10.3892/ol.2015.4033
MLA
Mostowska, A., Sajdak, S., Pawlik, P., Lianeri, M., Jagodzinski, P. P."Polymorphic variants in the vitamin D pathway genes and the risk of ovarian cancer among non-carriers of BRCA1/BRCA2 mutations". Oncology Letters 11.2 (2016): 1181-1188.
Chicago
Mostowska, A., Sajdak, S., Pawlik, P., Lianeri, M., Jagodzinski, P. P."Polymorphic variants in the vitamin D pathway genes and the risk of ovarian cancer among non-carriers of BRCA1/BRCA2 mutations". Oncology Letters 11, no. 2 (2016): 1181-1188. https://doi.org/10.3892/ol.2015.4033